A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines

Clinical Infectious Diseases

Volumn 55, Issue 6, 2012, Pages 825-834

  Erra, Elina O ^a,b   Askling, Helena Hervius ^c   Rombo, Lars ^c,d   Riutta, Jukka ^e   Vene, Sirkka ^f   Yoksan, Sutee ^g   Lindquist, Lars ^c   Pakkanen, Sari H ^a,b   Huhtamo, Eili ^a   Vapalahti, Olli ^a   Kantele, Anu ^a,b,e,h  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Sormland County Council   (Sweden)

^e Travel Clinic   (Finland)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^g MAHIDOL UNIVERSITY   (Thailand)

^h UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; JAPANESE ENCEPHALITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRAVEL; TREATMENT RESPONSE; VERO CELL; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; ENCEPHALITIS, JAPANESE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; MALE; MICE; MIDDLE AGED; NEUTRALIZATION TESTS; PROSPECTIVE STUDIES; TRAVEL; TRAVEL MEDICINE; VERO CELLS; VIRAL PLAQUE ASSAY; YOUNG ADULT;

EID: 84865475058     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis542     Document Type: Article

References (36)

1. World Health Organization. Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006; 81:331-40.
2. Pan XL, Liu H, Wang HY, et al. Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol 2011; 85:9847-53.
3. Li MH, Fu SH, Chen WX, et al. Genotype V Japanese encephalitis virus is emerging. PLoS Negl Trop Dis 2011; 5:e1231.
4. Solomon T. Control of Japanese encephalitis-within our grasp? N Engl J Med 2006; 355:869-71. (Pubitemid 44315979)
5. Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010; 82:930-6.
6. Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J Travel Med 2009; 16:217-9.
7. Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 2002; 35:183-8. (Pubitemid 34753904)
8. Fischer M, Lindsey N, Staples JE, Hills S, Centers for Disease Control and Prevention (CDC). Japanese encephalitis vaccines: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2010; 59:1-27.
9. Wilder-Smith A, Halstead SB. Japanese encephalitis: update on vaccines and vaccine recommendations. Curr Opin Infect Dis 2010; 23:426-31.
10. Lindsey NP, Staples JE, Jones JF, et al. Adverse event reports following Japanese encephalitis vaccination in the United States, 1999-2009. Vaccine 2010; 29:58-64.
11. Plesner AM, Arlien-Soborg P, Herning M. Neurological complications to vaccination against Japanese encephalitis. Eur J Neurol 1998; 5:479-85. (Pubitemid 28470002)
12. Ohtaki E, Matsuishi T, Hirano Y, Maekawa K. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). J Neurol Neurosurg Psychiatry 1995; 59:316-7.
13. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 1991; 337:1044.
14. Ruff TA, Eisen D, Fuller A, Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 1991; 338:881-2.
15. Sakaguchi M, Miyazawa H, Inouye S. Specific IgE and IgG to gelatin in children with systemic cutaneous reactions to Japanese encephalitis vaccines. Allergy 2001; 56:536-9. (Pubitemid 32521435)
16. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370:1847-53. (Pubitemid 350186053)
17. Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008; 198:493-9.
18. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008; 26:4382-6.
19. Dubischar-Kastner K, Eder S, Buerger V, et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2010; 28:5197-202.
20. Eder S, Dubischar-Kastner K, Firbas C, et al. Long term immunity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 2011; 29:2607-12.
21. Dubischar-Kastner K, Kaltenboeck A, Klingler A, Jilma B, Schuller E. Safety analysis of a Vero-cell culture derived Japanese encephalitis vaccine, IXIARO (IC51), in 6 months of follow-up. Vaccine 2010; 28:6463-9.
22. Schuller E, Klingler A, Dubischar-Kastner K, Dewasthaly S, Muller Z. Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO. Vaccine 2011; 29:8669-76.
23. Centers for Disease Control and Prevention (CDC). Recommendations for use of a booster dose of inactivated Vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:661-3.
24. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967; 99:285-90.
25. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September 2004. Vaccine 2005; 23:5205-11.
26. Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988; 319:608-14.
27. Henderson A. Immunisation against Japanese encephalitis in Nepal: experience of 1152 subjects. J R Army Med Corps 1984; 130: s188-91.
28. Poland JD, Cropp CB, Craven RB, Monath TP. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J Infect Dis 1990; 161:878-82. (Pubitemid 20148317)
29. Sanchez JL, Hoke CH, McCown J, et al. Further experience with Japanese encephalitis vaccine. Lancet 1990; 335:972-3. (Pubitemid 20135000)
30. Gambel JM, DeFraites R, Hoke C Jr, et al. Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series. J Infect Dis 1995; 171:1074.
31. Defraites RF, Gambel JM, Hoke CH Jr, et al. Japanese encephalitis vaccine (inactivated, BIKEN) in U.S. soldiers: immunogenicity and safety of vaccine administered in two dosing regimens. Am J Trop Med Hyg 1999; 61:288-93. (Pubitemid 29380263)
32. Hanna JN, Smith GA, McCulloch BG, Taylor CT, Pyke AT, Brookes DL. An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait. Aust N Z J Public Health 2005; 29:44-7. (Pubitemid 40378671)
33. Kurane I, Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 2000; 18(suppl 2):33-5. (Pubitemid 30252000)
34. Ferguson M, Johnes S, Li L, Heath A, Barrett A. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines-report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals 2008; 36:111-6. (Pubitemid 351282487)
35. Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-tickborne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008; 26:6151-6.
36. Kaltenbock A, Dubischar-Kastner K, Eder G, et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled phase 3 study. Vaccine 2009; 27:4483-9.